37 FFPE IMTs from 33 patients

Diagnostic ALK IHC (from clinical pathology reports)

26 ALK IHC+ (from 24 patients)

11 ALK IHC- (from 9 patients)

Targeted NGS

22/26 ALK IHC+ cases evaluable

20/22 contained ALK fusions

11/11 ALK IHC- cases evaluable

8/11 contained kinase fusions

2/11 contained ALK fusions

4/11 contained ROS1 fusions

2/11 contained PDGFRβ fusions

3/11 no kinase fusion identified

Overall, kinase gene fusions were identified in 28/33 (85%) of evaluable samples.

Lovly et al Fig. S2